Myeloma xenograft destruction by a nonviral vector delivering oncolytic infectious nucleic acid

Molecular Therapy

Volumn 19, Issue 6, 2011, Pages 1041-1047

  Hadac, Elizabeth M ^a   Kelly, Elizabeth J ^a   Russell, Stephen J ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ONCOLYTIC COXSACKIE VIRUS 21; ONCOLYTIC VIRUS; PLASMID DNA; RNA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE INCREASE; HUMAN; HUMAN CELL; MOUSE; MYELOMA; MYOSITIS; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; ONCOLYTIC VIROTHERAPY; TREATMENT OUTCOME; TUMOR REGRESSION; TUMOR XENOGRAFT; VIRION;

COXSACKIEVIRUS; MUS; PICORNAVIRIDAE;

EID: 85027956480     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2011.68     Document Type: Article

References (45)

1. Bernt, KM, Ni, S, Gaggar, A, Li, ZY, Shayakhmetov, DM and Lieber, A (2003). The effect of sequestration by nontarget tissues on anti-tumor effcacy of systemically applied, conditionally replicating adenovirus vectors. Mol Ther 8: 746-755. (Pubitemid 37527449)
2. Russell, SJ and Peng, KW (2007). Viruses as anticancer drugs. Trends Pharmacol Sci 28: 326-333. (Pubitemid 47016683)
3. Tao, N, Gao, G P, Parr, M, Johnston, J, Baradet, T, Wilson, JM et al. (2001). Sequestration of adenoviral vector by Kupffer cells leads to a nonlinear dose-response of transduction in liver. Mol Ther 3: 28-35. (Pubitemid 32509802)
4. Liu, C, Russell, SJ and Peng, KW (2010). Systemic therapy of disseminated myeloma in passively immunized mice using measles virus-infected cell carriers. Mol Ther 18: 1155-1164.
5. Mader, EK, Maeyama, Y, Lin, Y, Butler, GW, Russell, HM, Galanis, E et al. (2009). Mesenchymal stem cell carriers protect oncolytic measles viruses from antibody neutralization in an orthotopic ovarian cancer therapy model. Clin Cancer Res 15: 7246-7255.
6. Russell, SJ and Peng, KW (2008). The utility of cells as vehicles for oncolytic virus therapies. Curr Opin Mol Ther 10: 380-386.
7. Tseng, JC, Granot, T, DiGiacomo, V, Levin, B and Meruelo, D (2010). Enhanced specifc delivery and targeting of oncolytic Sindbis viral vectors by modulating vascular leakiness in tumor. Cancer Gene Ther 17: 244-255.
8. Wojton, J and Kaur, B (2010). Impact of tumor microenvironment on oncolytic viral therapy. Cytokine Growth Factor Rev 21: 127-134.
9. Working, PK, Lin, A and Borellini, F (2005). Meeting product development challenges in manufacturing clinical grade oncolytic adenoviruses. Oncogene 24: 7792-7801. (Pubitemid 41670680)
10. Yamaguchi, T and Uchida, E (2007). Regulatory aspects of oncolytic virus products. Curr Cancer Drug Targets 7: 203-208. (Pubitemid 46348635)
11. Al-Dosari, MS and Gao, X (2009). Nonviral gene delivery: principle, limitations, and recent progress. AAPS J 11: 671-681.
12. Li, S and Ma, Z (2001). Nonviral gene therapy. Curr Gene Ther 1: 201-226.
13. Ohlfest, JR, Freese, AB and Largaespada, DA (2005). Nonviral vectors for cancer gene therapy: prospects for integrating vectors and combination therapies. Curr Gene Ther 5: 629-641. (Pubitemid 43009507)
14. Sutton, PM (1991). Treatment of cancer by infectious nucleic acid. Lancet 337: 1553.
15. Carlisle, RC, Briggs, SS, Hale, AB, Green, NK, Fisher, KD, Etrych, T et al. (2006). Use of synthetic vectors for neutralising antibody resistant delivery of replicating adenovirus DNA. Gene Ther 13: 1579-1586. (Pubitemid 44688458)
16. Agol, VI, Pilipenko, EV and Slobodskaya, OR (1996). Modifcation of translational control elements as a new approach to design of attenuated picornavirus strains. J Biotechnol 44: 119-128. (Pubitemid 26056570)
17. Girard, M, Altmeyer, R, van der Werf, S, Wychowski, C and Martin, A (1995). The use of picornaviruses as vectors for the engineering of live recombinant vaccines. Biologicals 23: 165-169.
18. Nomoto, A, Iizuka, N, Kohara, M and Arita, M (1988). Strategy for construction of live picornavirus vaccines. Vaccine 6: 134-137. (Pubitemid 18089136)
19. Ochiai, H, Campbell, SA, Archer, GE, Chewning, TA, Dragunsky, E, Ivanov, A et al. (2006). Targeted therapy for glioblastoma multiforme neoplastic meningitis with intrathecal delivery of an oncolytic recombinant poliovirus. Clin Cancer Res 12: 1349-1354. (Pubitemid 43342528)
20. Reddy, PS, Burroughs, KD, Hales, LM, Ganesh, S, Jones, BH, Idamakanti, N et al. (2007). Seneca Valley virus, a systemically deliverable oncolytic picornavirus, and the treatment of neuroendocrine cancers. J Natl Cancer Inst 99: 1623-1633.
21. Sedmak, GV, Taylor, MW, Mealey, J Jr and Chen, TT (1972). Oncolytic effect of bovine enterovirus on mouse and human tumours. Nature New Biol 238: 7-9.
22. Roos, FC, Roberts, AM, Hwang, II, Moriyama, EH, Evans, AJ, Sybingco, S et al. (2010). Oncolytic targeting of renal cell carcinoma via encephalomyocarditis virus. EMBO Mol Med 2: 275-288.
23. Au, GG, Lincz, LF, Enno, A and Shafren, DR (2007). Oncolytic Coxsackievirus A21 as a novel therapy for multiple myeloma. Br J Haematol 137: 133-141. (Pubitemid 46474719)
24. Au, GG, Lindberg, AM, Barry, RD and Shafren, DR (2005). Oncolysis of vascular malignant human melanoma tumors by Coxsackievirus A21. Int J Oncol 26: 1471-1476.
25. Kelly, EJ, Hadac, EM, Greiner, S and Russell, SJ (2008). Engineering microRNA responsiveness to decrease virus pathogenicity. Nat Med 14: 1278-1283.
26. Hyypiä, T, Kallajoki, M, Maaronen, M, Stanway, G, Kandolf, R, Auvinen, P et al. (1993). Pathogenetic differences between coxsackie A and B virus infections in newborn mice. Virus Res 27: 71-78. (Pubitemid 23025587)
27. Buckland, FE, Bynoe, ML and Tyrrell, DA (1965). Experiments on the spread of colds. II. Studies in volunteers with coxsackievirus A21. J Hyg (Lond) 63: 327-343.
28. Dekel, B, Yoeli, R, Shulman, L, Padeh, S and Passwell, JH (2002). Localized thigh swelling mimicking a neoplastic process: involvement of coxsackie virus type A21. Acta Paediatr 91: 357-359. (Pubitemid 34270879)
29. Liu, TC, Galanis, E and Kirn, D (2007). Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress. Nat Clin Pract Oncol 4: 101-117. (Pubitemid 46189539)
30. Russell, SJ and Peng, KW (2009). Measles virus for cancer therapy. Curr Top Microbiol Immunol 330: 213-241.
31. García-Sastre, A and Palese, P (1993). Genetic manipulation of negative-strand RNA virus genomes. Annu Rev Microbiol 47: 765-790. (Pubitemid 23302952)
32. Palese, P, Zheng, H, Engelhardt, OG, Pleschka, S and García- Sastre, A (1996). Negative-strand RNA viruses: genetic engineering and applications. Proc Natl Acad Sci USA 93: 11354-11358. (Pubitemid 26347125)
33. Van Den Wollenberg, DJ, Van Den Hengel, SK, Dautzenberg, IJ, Kranenburg, O and Hoeben, RC (2009). Modifcation of mammalian reoviruses for use as oncolytic agents. Expert Opin Biol Ther 9: 1509-1520.
34. Marconi, P, Argnani, R, Epstein, AL and Manservigi, R (2009). HSV as a vector in vaccine development and gene therapy. Adv Exp Med Biol 655: 118-144.
35. Guo, ZS and Bartlett, DL (2004). Vaccinia as a vector for gene delivery. Expert Opin Biol Ther 4: 901-917. (Pubitemid 38843227)
36. Thorne, SH, Hwang, TH and Kirn, DH (2005). Vaccinia virus and oncolytic virotherapy of cancer. Curr Opin Mol Ther 7: 359-365. (Pubitemid 41103056)
37. Ponnazhagan, S (2004). Parvovirus vectors for cancer gene therapy. Expert Opin Biol Ther 4: 53-64. (Pubitemid 38057266)
38. Atkins, GJ, Smyth, JW, Fleeton, MN, Galbraith, SE and Sheahan, BJ (2004). Alphaviruses and their derived vectors as anti-tumor agents. Curr Cancer Drug Targets 4: 597-607. (Pubitemid 39536380)
39. Tai, CK and Kasahara, N (2008). Replication-competent retrovirus vectors for cancer gene therapy. Front Biosci 13: 3083-3095. (Pubitemid 351589220)
40. Alvarez-Salas, LM (2008). Nucleic acids as therapeutic agents. Curr Top Med Chem 8: 1379-1404.
41. Yamamoto, A, Kormann, M, Rosenecker, J and Rudolph, C (2009). Current prospects for mRNA gene delivery. Eur J Pharm Biopharm 71: 484-489.
42. Higuchi, Y, Kawakami, S and Hashida, M (2010). Strategies for in vivo delivery of siRNAs: recent progress. BioDrugs 24: 195-205.
43. Schroeder, A, Levins, CG, Cortez, C, Langer, R and Anderson, DG (2010). Lipid-based nanotherapeutics for siRNA delivery. J Intern Med 267: 9-21.
44. Shafren, DR, Dorahy, DJ, Greive, SJ, Burns, GF and Barry, RD (1997). Mouse cells expressing human intercellular adhesion molecule-1 are susceptible to infection by coxsackievirus A21. J Virol 71: 785-789.
45. Racaniello, VR and Baltimore, D (1981). Cloned poliovirus complementary DNA is infectious in mammalian cells. Science 214: 916-919 (Pubitemid 12220092)